Local treatment of acquired melanin hyperpigmentation including melasma, post-inflammatory and chemical melanosis (perfume)

Two applications, per day.

The rate of application may be reduced as the depigmentation progresses, and it is preferable to continue the treatment at least once a week. It is necessary to ensure local photoprotection.

Pharmacotherapeutic group: DEPIGMENTING AGENT

(D: Dermatology)

Mequinol is the monomethyl ether of hydroquinone. It exerts a depigmenting action by inhibiting the synthesis of melanin.

Without object.

Hypersensitivity to mequinol.

Child under 12 years of age.

Avoid exposure to sunlight in hyperpigmented areas or ensure local photoprotection both during treatment and after sunscreen treatment with full screen
< Br>

Avoid contact with eyes and mucous membranes.

This medicinal product contains lanolin (wool fat) and may cause local skin reactions (eg eczema).


Without object.

Without object.

Pregnancy

In clinical studies, no malformative or fetotoxic effects have been observed to date. However, monitoring of pregnancies exposed to mequinol is insufficient to exclude any risk.

Therefore, as a precautionary measure, it is preferable not to use this medication during pregnancy.


In the absence of data, the use of this medication should be avoided during breastfeeding

Reactions, type of irritation or sensitization to mequinol (rare).

Risk of post-inflammatory hypermelanosis.

Cases of leucomelanoderma, inhomogeneous with confetti depigmentation at the site of application and some cases of hypomelanosis occurring remote from the treated areas have been reported. Code>
Local treatment of acquired melanin hyperpigmentation including melasma, post-inflammatory and chemical melanosis (perfume)